Overview
Pramlintide is a synthetic analog of human amylin cosecreted with insulin by pancreatic beta cells; reduces postprandial glucose increases via the following mechanisms: 1) prolongation of gastric emptying time, 2) reduction of postprandial glucagon secretion, and 3) reduction of caloric intake through centrally-mediated appetite suppression. Pramlintide is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Symlin Pen, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs or
Authorization may be granted when all of the following criteria are met, and documentation has been provided:
1. The patient has a diagnosis of type 1 or type 2 diabetes mellitus
2. The patient is currently receiving optimal mealtime insulin therapy
3. The patient has experienced an inadequate treatment response to insulin
4. The patient does not require drug therapy to stimulate gastrointestinal motility

Continuation of Therapy
Reauthorization may be granted when a physician’s assessment has been submitted documenting the patient has had an expected reduction in HbA1c since starting Symlin therapy.

Limitations
1. Authorizations will be granted for 36 months
References
1. Symlin (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2019

Review History
04/2017 – Reviewed
04/17/2019 – Reviewed
05/20/2020 – Reviewed and Updated May P&T Mtg; updated overview and references; removed rationale from criteria; added started and stabilized statement. Effective 8/1/20.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.